ReviewJournal of hematology & oncology2015
Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib.
Rossana Maffei et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
30 papers cite it
this paperpooled itcites it